CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
mavacamtendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04766892
NCT04766892Phase 2Completed
CompareCT.gov

An Exploratory, Open-label, Proof-of-concept, Phase 2a Study of Mavacamten (MYK-461) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Chronic Elevation of Cardiac Biomarkers

Bristol-Myers Squibb·interventional·Posted Feb 23, 2021·Updated Mar 20, 2025

In Brief

A Phase 2 clinical trial evaluating mavacamten for Heart Failure With Preserved Ejection Fraction. Completed, enrolled 30 participants across 21 sites in 2 countries.

Detailed Summary

This is a Phase 2a proof-of-concept study to assess safety, tolerability, and preliminary efficacy of mavacamten treatment on biomarker levels in participants with heart failure with preserved ejection fraction (HFpEF) and elevation of NT-proBNP with or without elevation of cTnT. Data from this study will inform future study designs of mavacamten in patients with HFpEF.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure With Preserved Ejection Fraction
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedFeb 23, 2021
Enrollment StartMar 30, 2021
Primary CompletionFeb 26, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 5.4 years ago

Interventions

mavacamtendrug

mavacamten capsules